Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046732 | 0.85 | PDPK1 (0.53) | PDPK1MTORGBA1SIGMAR1 | |
| SCHEMBL3073767 | 0.85 | GBA1 (0.45) | OPRM1OPRD1GBA1SLC6A3HTR2A | |
| SCHEMBL3082847 | 0.83 | OPRM1 (0.46) | OPRM1OPRD1GBA1HTR2AKCNH2 | |
| SCHEMBL3075531 | 0.81 | OPRM1 (0.44) | PDPK1MTOROPRM1OPRD1GBA1 | |
| SCHEMBL6407587 | 0.79 | OPRM1 (0.42) | OPRM1OPRD1GBA1HTR2AKCNH2 | |
| SCHEMBL7047341 | 0.75 | INPP5A (0.43) | — | |
| SCHEMBL7050749 | 0.74 | PDPK1 (0.45) | PDPK1MTOR | |
| SCHEMBL7049028 | 0.72 | INPP5A (0.41) | — | |
| SCHEMBL11227003 | 0.71 | GBA1 (0.61) | OPRM1OPRD1GBA1SLC6A3SIGMAR1 | |
| SCHEMBL7114787 | 0.71 | PDPK1 (0.42) | PDPK1MTOROPRM1OPRD1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
| US-20090175924-A1 | COATED STENT | BIONERIS AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-1390045-B1 | THE USE OF A COMPOUND WITH A NEGATIVELY CHARGED DOMAIN OF PHOSPHOROUS-CONTAINING RADICALS FOR THE TREATMENT OF RESTENOSIS | BIONERIS AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20050261756-A1 | Coated stent | BIONERIS AB (SE) | 2005-11-24 | — | — | US | disclosed |
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | PERSTORP AB (SE) | 2005-10-13 | — | — | US | disclosed |
| US-6949517-B1 | Method of treating inflammatory, tissue repair and infectious conditions | SIREN MATTI | 2005-09-27 | — | — | US | disclosed |
| EP-1545643-A1 | COATED STENT | Bioneris AB, (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | BIONERIS AB (SE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004022123-A1 | COATED STENT | BIONERIS AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| EP-0910383-B1 | THE USE OF GROWTH FACTOR MODULATING COMPOUNDS | BIONERIS AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| US-6632797-B2 | Administering to a mammal a cyclic compound (acyclic, carbocyclic or heterocyclic) substituted by at least three vicinal phosphorus containing radicals for treating angiogenesis in tumor conditions | SIREN MATTI (FI) | 2003-10-14 | — | — | US | disclosed |
| EP-1023301-B1 | A HETEROCYCLIC CHEMICAL COMPOUND | BIONERIS AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| EP-1216705-A2 | The use of growth factor modulation compounds substituted with three vicinal phosphorus containing radical in the manufacture of a medicament for tissue repair | PERSTORP AB (SE) | 2002-06-26 | — | — | EP | disclosed |
| US-20020065253-A1 | Use of growth factor modulating compounds | SIREN MATTI (FI) | 2002-05-30 | — | — | US | disclosed |
| US-6046334-A | Heterocyclic chemical compound | PERSTORP AB (SE) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | PDPK1 3190/4885MTOR 1812/4885OPRM1 53/4885 |
| US-20020065253-A1 | Use of growth factor modulating compounds | HDGF, PGF, FGF2 | PDPK1 1548/4885MTOR 505/4885OPRM1 990/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | PDPK1 3837/4885MTOR 1905/4885OPRM1 498/4885 |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | PCNA, OPRK1, OGFR | PDPK1 2350/4885MTOR 1669/4885OPRM1 32/4885 |
| US-20090175924-A1 | COATED STENT | PHOSPHO1, SOST, PLCB3 | PDPK1 463/4885MTOR 18/4885OPRM1 68/4885 |
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | TNF, TLR2, TPMT | PDPK1 1842/4885MTOR 819/4885OPRM1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.